HRP980591A2 - Novel heterocyclically substituted alpha-hydroxycarboxylic acid derivatives, their preparation and use as endothelin receptor antagonists - Google Patents
Novel heterocyclically substituted alpha-hydroxycarboxylic acid derivatives, their preparation and use as endothelin receptor antagonistsInfo
- Publication number
- HRP980591A2 HRP980591A2 HR19750529.5A HRP980591A HRP980591A2 HR P980591 A2 HRP980591 A2 HR P980591A2 HR P980591 A HRP980591 A HR P980591A HR P980591 A2 HRP980591 A2 HR P980591A2
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- substituted
- unsubstituted
- phenyl
- hydrogen
- Prior art date
Links
- 229940118365 Endothelin receptor antagonist Drugs 0.000 title claims description 11
- 239000002308 endothelin receptor antagonist Substances 0.000 title claims description 11
- 238000002360 preparation method Methods 0.000 title description 5
- -1 alkali metal cation Chemical class 0.000 claims description 76
- 229910052736 halogen Inorganic materials 0.000 claims description 39
- 150000002367 halogens Chemical class 0.000 claims description 39
- 150000001875 compounds Chemical class 0.000 claims description 35
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 26
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- 239000001301 oxygen Substances 0.000 claims description 23
- 229910052717 sulfur Inorganic materials 0.000 claims description 23
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 20
- 239000011593 sulfur Chemical group 0.000 claims description 20
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 19
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 14
- 102000002045 Endothelin Human genes 0.000 claims description 12
- 108050009340 Endothelin Proteins 0.000 claims description 12
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 12
- 125000001624 naphthyl group Chemical group 0.000 claims description 10
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 8
- 125000002947 alkylene group Chemical group 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 7
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- 229910052783 alkali metal Inorganic materials 0.000 claims description 5
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 125000004450 alkenylene group Chemical group 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims description 3
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 230000036454 renin-angiotensin system Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 239000005541 ACE inhibitor Substances 0.000 claims description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 2
- 229940123413 Angiotensin II antagonist Drugs 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 208000033626 Renal failure acute Diseases 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 201000011040 acute kidney failure Diseases 0.000 claims description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 2
- 239000002876 beta blocker Substances 0.000 claims description 2
- 229940097320 beta blocking agent Drugs 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 2
- 239000002934 diuretic Substances 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 239000002461 renin inhibitor Substances 0.000 claims description 2
- 229940086526 renin-inhibitors Drugs 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 10
- 150000002431 hydrogen Chemical group 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 4
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 claims 2
- 102000003729 Neprilysin Human genes 0.000 claims 2
- 108090000028 Neprilysin Proteins 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 description 25
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 description 16
- 125000004093 cyano group Chemical group *C#N 0.000 description 13
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 10
- 230000027455 binding Effects 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102100033902 Endothelin-1 Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 125000003396 thiol group Chemical class [H]S* 0.000 description 5
- WGPALANGDJYHHU-GOSISDBHSA-N (2s)-2-[(4,5-dimethyl-1,3-thiazol-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=C(C)S1 WGPALANGDJYHHU-GOSISDBHSA-N 0.000 description 4
- 101800004490 Endothelin-1 Proteins 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 150000003857 carboxamides Chemical class 0.000 description 4
- 150000001735 carboxylic acids Chemical class 0.000 description 4
- FONOSWYYBCBQGN-UHFFFAOYSA-N ethylene dione Chemical group O=C=C=O FONOSWYYBCBQGN-UHFFFAOYSA-N 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- TWAYCFHPZZAERR-UHFFFAOYSA-N 4,5-dimethyl-2-methylsulfonyl-1,3-oxazole Chemical compound CC=1N=C(S(C)(=O)=O)OC=1C TWAYCFHPZZAERR-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 102100040611 Endothelin receptor type B Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001342 alkaline earth metals Chemical class 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 235000019345 sodium thiosulphate Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- QYDPEPDIZMJWCM-HXUWFJFHSA-N (2s)-2-(1,3-benzothiazol-2-yloxy)-3-methoxy-3,3-diphenylpropanoic acid Chemical compound C=1C=CC=CC=1C([C@H](OC=1SC2=CC=CC=C2N=1)C(O)=O)(OC)C1=CC=CC=C1 QYDPEPDIZMJWCM-HXUWFJFHSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- VIROVYVQCGLCII-UHFFFAOYSA-N amobarbital Chemical compound CC(C)CCC1(CC)C(=O)NC(=O)NC1=O VIROVYVQCGLCII-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- HZZGDPLAJHVHSP-GKHTVLBPSA-N big endothelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CN=CN1 HZZGDPLAJHVHSP-GKHTVLBPSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 208000001286 intracranial vasospasm Diseases 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
- 125000004711 1,1-dimethylethylthio group Chemical group CC(C)(S*)C 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- 125000004776 1-fluoroethyl group Chemical group [H]C([H])([H])C([H])(F)* 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000004781 2,2-dichloro-2-fluoroethyl group Chemical group [H]C([H])(*)C(F)(Cl)Cl 0.000 description 1
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- SRXFXCKTIGELTI-UHFFFAOYSA-N 2-(4-chlorophenyl)ethanamine Chemical compound NCCC1=CC=C(Cl)C=C1 SRXFXCKTIGELTI-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000004780 2-chloro-2,2-difluoroethyl group Chemical group [H]C([H])(*)C(F)(F)Cl 0.000 description 1
- AXDZFGRFZOQVBV-UHFFFAOYSA-N 2-chlorocyclopentan-1-one Chemical compound ClC1CCCC1=O AXDZFGRFZOQVBV-UHFFFAOYSA-N 0.000 description 1
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- ZBZAJWMLUGDFDM-UHFFFAOYSA-N 4,5-dimethyl-2-methylsulfanyl-1,3-thiazole Chemical compound CSC1=NC(C)=C(C)S1 ZBZAJWMLUGDFDM-UHFFFAOYSA-N 0.000 description 1
- QLDXVXIEWBKLEC-UHFFFAOYSA-N 4,5-dimethyl-2-methylsulfonyl-1,3-thiazole Chemical compound CC=1N=C(S(C)(=O)=O)SC=1C QLDXVXIEWBKLEC-UHFFFAOYSA-N 0.000 description 1
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000010180 Endothelin receptor Human genes 0.000 description 1
- 108050001739 Endothelin receptor Proteins 0.000 description 1
- 102400000686 Endothelin-1 Human genes 0.000 description 1
- 206010014824 Endotoxic shock Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- KURZCZMGELAPSV-UHFFFAOYSA-N [Br].[I] Chemical compound [Br].[I] KURZCZMGELAPSV-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- JYNZIOFUHBJABQ-UHFFFAOYSA-N allyl-{6-[3-(4-bromo-phenyl)-benzofuran-6-yloxy]-hexyl-}-methyl-amin Chemical compound C=1OC2=CC(OCCCCCCN(C)CC=C)=CC=C2C=1C1=CC=C(Br)C=C1 JYNZIOFUHBJABQ-UHFFFAOYSA-N 0.000 description 1
- 125000005336 allyloxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- YNNGZCVDIREDDK-UHFFFAOYSA-N aminocarbamodithioic acid Chemical compound NNC(S)=S YNNGZCVDIREDDK-UHFFFAOYSA-N 0.000 description 1
- 229960001301 amobarbital Drugs 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 150000005840 aryl radicals Chemical class 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 125000004775 chlorodifluoromethyl group Chemical group FC(F)(Cl)* 0.000 description 1
- HRYZWHHZPQKTII-UHFFFAOYSA-N chloroethane Chemical compound CCCl HRYZWHHZPQKTII-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 125000004774 dichlorofluoromethyl group Chemical group FC(Cl)(Cl)* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 229960003750 ethyl chloride Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000004672 ethylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- LPAGFVYQRIESJQ-UHFFFAOYSA-N indoline Chemical compound C1=CC=C2NCCC2=C1 LPAGFVYQRIESJQ-UHFFFAOYSA-N 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- AFRJJFRNGGLMDW-UHFFFAOYSA-N lithium amide Chemical compound [Li+].[NH2-] AFRJJFRNGGLMDW-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002902 organometallic compounds Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 206010038464 renal hypertension Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007885 tablet disintegrant Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000005147 toluenesulfonyl group Chemical group C=1(C(=CC=CC1)S(=O)(=O)*)C 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- CMMXCVYESRODNH-UHFFFAOYSA-N trichloroepoxyethane Chemical class ClC1OC1(Cl)Cl CMMXCVYESRODNH-UHFFFAOYSA-N 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002525 vasculotropin inhibitor Substances 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/12—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/38—One oxygen atom attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Predloženi izum odnosi se na nove derivate karboksilnih kiselina, njihovo pripravljanje i upotrebu.
Endotelin je peptid izgrađen od 21 amino kiseline, kojeg sintetizira i oslobađa vaskularni endotel. Endotelin postoji u tri izomerna oblika, ET-1, ET-2 i ET-3. Kako se ovdje rabi, pojam "endotelin" ili "ET" odnosi se na jedan ili na sve izomerne oblike endotelina. Endotelin je jaki vazokonstriktor i snažno djeluje na tonus krvnih žila. Poznato je, da tu vazokonstrikciju uzrokuje vezanje endotelina na njegov receptor (Nature, 332, 411-415, 1988; FEBS Letters, 231, 440-444, 1988 i Biochem. Biophys. Res. Commun., 154, (1988), 868-875).
Povišeno ili nenormalno oslobađanje endotelina uzrokuje trajno sužavanje u perifernim, renalnim i cerebralnim krvnim žilama, koje može dovesti do zdravstvenih poremećaja. Iz literature je poznato da je endotelin uključen u brojne zdravstvene poremećaje. To su hipertenzija, akutni miokardijalni infarkt, plućna hipertenzija, Raynaudov sindrom, cerebralne vazospazme, udar, benigna hipertrofija prostate, ateroskleroza, astma i rak prostate (J. Vascular Med. Biology 2, (1990) 207, J. Am. Med. Association 264, (1990) 2868, Nature 344, (1990) 114, N. Engl. J. Med. 322, (1989) 205, N. Engl. J. Med. 328, (1993) 1732, Nephron 66, (1994) 373, Stroke 25, (1994) 904, Nature 365, (1993) 759, J. Mol. Ćeli. Cardiol. 27, (1995) A234, Cancer Research 56, (1996) 663, Nature Medicine 1, (1995), 944).
Zasada su u literaturi opisana najmanje dva podtipa endotelin-receptora, ETA i ETB receptori (Nature 348, (1990) 730, Nature 348, (1990) 732) . Prema tome, tvari koje inhibiraju vezanje% endotelina na jedan ili na obadva receptora, moraju aritagonizirati fiziološke efekte endotelina i stoga predstavljaju dragocjene lijekove.
Cilj predloženog izuma je dati endotelin receptor antagoniste koji se mogu vezati na ETA i/ili ETB receptor.
Mi smo pronašli da se taj cilj može postići s derivatima heterociklički supstituiranih α-hidroksi-karboksilnih kiselina formule I
[image]
u kojoj
R1 predstavlja tetrazol ili skupinu
[image]
u kojoj
R ima slijedeća značenja:
a) radikal OR5 gdje R5 predstavlja
vodik, kation alkalijskog metala, kation zemno alkalijskog metala ili fiziološki podnošljiv organski amonijev ion, kao što je tercijarni C1-C4-alkil-amonijev ili amonijev ion;
C3-C8-cikloalkil, C1-C8-alkil, CH2-fenil, koji može biti supstituirani s jednim ili više slijedećih radikala: halogen, nitro, cijano, C1-C4-alkil, C1-C4-haloalkil, hidroksil, C1-C4-alkoksi, merkapto, C1-C4-alkiltiol- amino, NH (C1-C4-alkil),N (C1-C4-alkil)2;
C3-C8-alkenilnu ili C3-C8-alkinilnu skupinu, pri čemu te skupine, sa svoje strane, mogu nositi jedan do pet halogenih atoma;
R5 također može biti fenilni radikal koji može nositi jedan do pet halogenih atoma i/ili jedan do tri slijedeća radikala: nitro, cijano, C1-C4-alkil, C1-C4-haloalkil, hidroksil, C1-C4-alkoksi, merkapto, C1-C4-alkiltio, amino, NH(C1-C4-alkil),N (C1-C4-alkil)2 .
b) peteročlani heteroaromatski sistem povezan preko dušikovog atoma, kao pirolil, pirazolil, imidazolil i triazolil, koji može nositi jedan ili dva halogena atoma, ili jednu ili dvije C1-C4-alkilne ili jednu ili dvije C1-C4-alkoksi skupine,
c) skupina
[image]
u kojoj k može imati vrijednost 0, 1 i 2, p može biti 1, 2, 3 i 4 i R6 je
C1-C4-alkil, C3-C8-cikloalkil, C3-C8-alkenil, C3-C8-alkinil ili fenil, koji može biti jednostruko do trostruko supstituiran s halogenim, nitro, cijano, C1-C4-alkilom, hidroksilom, C1-C4-alkoksi, C1-C4-alkiltio, amino, NH(C1-C4-alkil),N (C1-C4-alkilom)2, merkapto.
d) radikal formule
[image]
u kojoj R7 je
C1-C4-alkil, C3-C8-alkenil, C3-C8-alkinil, C3-C8-cikloalkil, pri čemu ti radikali mogu nositi C1-C4-alkoksi, C1-C4-alkiltio i/ili fenilni radikal kao je definiran pod c);
C1-C4-haloalkil ili fenil, koji može biti supstituiran kako je navedeno pod c).
Ostali supstituenti imaju slijedeća značenja:
A je NR8R9, azido, OR10, SR10 ili C1-C4-alkil.
X je kisik, sumpor, CR11 ili NR12; pod uvjetom da ako X = CR11, tada Y = kisik ili sumpor ili NR14.
Y je kisik, sumpor, CR13 ili NR14; pod uvjetom da ako Y = kisik ili sumpor ili NR14, tada X = CR11.
R2 i R3 (koji mogu biti jednaki ili različiti) predstavljaju:
fenil ili naftil, koji može biti supstituiran s jednim ili više slijedećih radikala: halogen, nitro, cijano, hidroksil, merkapto, C1-C4-alkil, C2-C4-alkenil, C2-C4-alkinil, C1-C4-haloalkil, C1-C4-alkoksi, fenoksi, C1-C4-haloalkoksi, C1-C4-alkiltio, amino, NH (C1-C4-alkil) , N(C1-C4-alkil)2 ili fenil, koji može biti jednostruko ili višestruko supstituiran, npr. jednostruko do trostruko, s halogenim, nitro, cijano, C1-C4-alkilom, C1-C4-haloalkilom, C1-C4-alkoksi, C1-C4-haloalkoksi iliC1-C4- alkiltio; ili
fenil ili naftil, koji su međusobno povezani u orto položajima preko izravne veze, metilenske, etilenske ili etenilne skupine, kisikovog ili sumpornog atoma ili jedne SO2-, NH ili N(C1-C4-alkilne) skupine; C5-C6-cikloalkil, pri čemu tu radikali u svakom slučaju mogu biti jednostruko ili višestruko supstituirani s halogenim, hidroksilom, merkapto, karboksilom, nitro, cijano, C1-C4-alkilom, C2-C4-alkenilom, C2-C4-alkinilom, C1-C4- alkoksi,C1-C4-alkiltio, C1-C4-haloalkoksi.
R4 i R11 (koji mogu biti jednaki ili različiti) predstavljaju: vodik, halogen, C1-C4-alkoksi, C1-C4-haloalkoksi, C3-C6-alkeniloksi, C3-C6-alkiniloksi, C1-C4-alkiltio, C1-C4-alkilkarbonil, C1-C4-alkoksikarbonil, hidroksil, NH2, NH (C1-C4-alkil), N(C1-C4-alkil)2C1-C4-alkil, C2-C4-alkenil, C2-C4-alkinil, pri čemu ovi radikali mogu biti supstituirani s halogenim, hidroksilom, merkapto, karboksilom, cijano; ili CR4 zajedno sa CR11 tvori petero- ili šesteročlani alkilenski ili alkenilenski prsten može biti nesupstituiran ili supstituiran, i u kojem u svakom slučaju jedna ili više metilenskih skupina može biti nadomješteno s kisikom, sumporom, -NH ili NH(C1-C4-alkilom).
R8 je vodik, C1-C8-alkil, C3-C8-alkenil ili C3-C8-alkinil, C1-C5-alkilkarbonil, pri čemu ovi radikali u svakom slučaju mogu biti jednostruko ili višestruko supstituirani s halogenim, hidroksilom, merkapto, karboksilom, nitro, amino, cijano, C1-C4-alkoksi, C3-C6-alkeniloksi, C3-C6-alkiniloksi, C1-C4-alkiltio, C1-C4-halo-alkoksi, C1-C4-alkoksikarbonilom, C3-C8-alkilkarbonil-alkilom, NH (C1-C4-alkilom) , N (C1-C4-alkilom)2, C3-C8-ciklo-alkilom, fenoksi ili fenilom, pri čemu spomenuti radikali sa svoje strane mogu biti jednostruko ili višestruko, npr. jednostruko do trostruko supstituirani s halogenim, hidroksilom, merkapto, karboksilom, nitro, cijano, C1-C4-alkilom, C1-C4-haloalkilom, C1-C4-alkoksi, C1-C4-haloalkoksi, amino, NH (C1-C4-alkilom) , N (C1-C4-alkilom)2, fenilom ili C1-C4-alkiltio; fenil ili naftil, koji u svakom slučaju mogu biti supstituirani s jednim ili više slijedećih radikala: halogeni, nitro, cijano, hidroksil, amino, C1-C4-alkil, C1-C4-haloalkil, C1-C4-alkoksi, C1-C4-haloalkoksi, fenoksi, C1-C4-alkiltio, NH (C1-C4-alkil) , N (C1-C4-alkil)2, dioksimetilen ili dioksoetilen; C3-C8-cikloalkil, pri čemu ti radikali u svakom slučaju mogu biti jednostruko ili višestruko supstituirani s halogenim, hidroksilom, merkapto, karboksilom, nitro, cijano, C1-C4-alkilom, C2-C4-alkenilom, C2-C4-alkinilom, C1-C4-alkoksi,C1-C4-alkiltio, C1-C4-haloalkoksi;
ili R8 zajedno sa R9 tvori C3-C7-alkilenski lanac zatvoren u prsten, koji može biti jednostruko ili višestruko supstituiran sa C1-C4-alkilomf C1-C4-alkiltio, C1-C4-alkoksi, C1-C4-haloalkilom, C1-C4-haloalkoksi, i u kojem alkilenska skupina može biti nadomještena s kisikom ili sumporom, kao -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)7-, - (CH2)2-O-(CH2)2-,- (CH2)2-S- (CH2)2- .
R9 je vodik, C1-C4-alkil;
ili R9 je povezan s R8 u prsten, kako je navedeno kod R8.
R10 je vodik, C1-C8-alkil, C3-C8-alkenil ili C3-C8-alkinil, pri čemu ovi radikali u svakom slučaju mogu biti jednostruko ili višestruko supstituirani s halogenim, hidroksilom, merkapto, karboksilom, nitro, amino, cijano, C1-C4-alkoksi, C3-C6-alkeniloksi, C3-C6-alkiniloksi, C1-C4-alkiltio, C1-C4-haloalkoksi, C1-C4-alkoksikarbonilom, C3-C8-alkilkarbonilalkilom, karboksamidom, CONH (C1-C4-alkilom) , CON (C1-C4-alkilom)2, CONR15R16, NH (C1-C4-alkilom) , N (C1-C4-alkilom)2, C3-C8-cikloalkilom, heteroariloksi ili heteroarilom, koji je petero- ili šesteročlani, i koji uključuje jedan do tri dušikova atoma i/ili atom sumpora ili kisika, fenoksi ili fenil, pri čemu svi spomenuti arilni radikali,
sa svoje strane, mogu biti jednostruko ili višestruko, npr. jednostruko do trostruko supstituirani s halogenim, hidroksilom, merkapto, karboksilom, nitro, cijano, C1-C4-alkilom, C1-C4-alkilkarboksilom, R19, C1-C4-haloalkilom, C1-C4-alkoksi, C1-C4-haloalkoksi, amino, NH (C1-C4-alkilom), N (C1-C4-alkilom)2, fenilom ili C1-C4-alkiltio;
fenil ili naftil, koji u svakom slučaju može biti jednostruko ili višestruko supstituiran sa slijedećim radijalima: halogenim, nitro, cijano, hidroksil, amino, C1-C4-alkil, C1-C4-haloalkil, C1-C4-alkoksi, C1-C4-haloalkoksi, fenoksi, C1-C4-alkiltio, NH (C1-C4-alkil), N (C1-C4-alkil)2, dioksimetilen ili dioksoetilen;
C3-C8-cikloalkil, pri čemu ti radikali u svakom slučaju mogu biti jednostruko do trostruko supstituirani s halogenim, hidroksilom, merkapto, karboksilom, nitro, cijano, C1-C4-alkilom, C2-C4-alkenilom, C2-C4-alkinilom, C1-C4-alkoksi, C1-C4-alkiltio, C1-C4-haloalkoksi.
R12 je vodik, C1-C4-alkil; ili NR12 zajedno sa CR4 tvori petero- ili šesteročlani alkilenski ili alkenilenski prsten, koji može jednostruko do trostruko supstituiran sa C1-C4-alkilom, i u kojem u svakom slučaju jedna ili više metilenskih skupina kiselina može biti nadomješteno s kisikom ili sumporom;
R13 je vodik, halogen, C1-C4-alkil, C2-C4-alkenil, pri čemu ti radikali mogu biti supstituirani s halogenim.
R14 je vodik, C1-C4-alkil.
R15 i R16 zajedno tvore C3-C7-alkilenski ili C4-C7-alkenilenski lanac zatvoren u prsten na koji može biti fuzioniran fenilni prsten koji može biti jednostruko do trostruko supstituiran s halogenim, C1-C4-alkilom, C1-C4-alkiltio, C1-C4-alkoksi, C1-C4-haloalkilom, C1-C4-haloalkoksi, hidroksilom, karboksilom, amino.
R19 je C1-C4-alkil, C1-C4-alkiltio, C1-C4-alkoksi, koji može nositi slijedeće radikale; hidroksil, karboksil, C1-C4-alkoksikarbonil, amino, NH (C1-C4-alkil) , N (C1-C4-alkil)2, karboksamid ili CON (C1-C4-alkil)2.
Ovdje i u slijedećem tekstu primjenjuju se slijedeće definicije:
Alkalijski metal je npr. litij, natrij, kalij.
Zemno alkalijski metal je npr. kalcij/- magnezij, barij.
C3-C8-cikloalkil je npr. ciklopropil, ciklobutil, ciklopentil, cikloheksil, cikloheptil ili ciklooktil;
C1-C4-haloalkil može biti linearan ili razgranat, kao npr. fluormetil, difluormetil, trifluormetil, klor-difluormetil, diklorfluormetil, triklormetil, 1-fluoretil, 2-fluoretil, 2,2-difluoretil, 2,2,2-trifluoretil, 2-klor-2,2-difluoretil, 2,2-diklor-2-fluoretil, 2,2,2-trikloretil ili pentafluoretil;
C1-C4-haloalkoksi može biti linearan ili razgranat, kao npr. difluormetoksi, trifluormetoksi, klordifluor-metoksi, 1-fluoretoksi, 2,2-difluoretoksi, 1,1,2,2-tetra-fluoretoksi, 2,2,2-trifluoretoksi, 2-klor-1,1,2-trifluoretoksi, 2-fluoretoksi ili pentafluoretoksi;
C1-C4-alkil može biti linearan ili razgranat, kao npr. metil, etil, 1-propil, 2-propil, 2-metil-2-propil, 2-metil-1-propil, 1-butil ili 2-butil;
C2-C4-alkenil može biti linearan ili razgranat, kao npr. etenil, 1-propen-3-il, 2-propen-3-il, 1-propen-1-il, 2-metil -1-propenil, 1-butenil ili 2-butenil;
C2-C4-alkinil može biti linearan ili razgranat, kao npr. etinil, 1-propin-1-il, 1-propin-3-il, 1-butin-4-il ili 2-butin-4-il;
C1-C4-alkoksi može biti linearan ili razgranat, kao npr. metoksi, etoksi, propoksi, 1-metiletoki, butoksi, 1-metilpropoksi, 2-metilpropoksi ili 1,1-dimetiletoksi;
C3-C6-alkeniloksi može biti linearan ili razgranat, kao npr. aliloksi, 2-buten-1-iloksi ili 3-buten-2-iloksi;
C3-C6-alkiniloksi može biti linearan ili razgranat, kao npr. 2-propin-1-iloksi, 2-butin-1-iloksi ili 3-butin-2-iloksi;
C1-C4-alkiltio može biti linearan ili razgranat, kao npr. metiltio, etiltio, propiltio, 1-metiletiltio, butiltio, 1-metilpropiltio, 2-metilpropiltio ili 1,1-dimetiletiltio;
C1-C4-alkilkarbonil može biti linearan ili razgranat, kao npr. acetil, etilkarbonil ili 2-propilkarbonil;
C1-C4-alkoksikarbonil može biti linearan ili razgranat, kao npr. metoksikarbonil, etoksikarbonil, n-propoksikarbonil, i-propoksikarbonil ili n-butoksi-karbonil;
C3-C8-alkilkarbonilalkil može biti linearan ili razgranat, kao npr. 2-okso-prop-1-il, 3-okso-but-1-il ili 3-okso-but-2-il;
C1-C8-alkil može biti linearan ili razgranat, kao npr. C1-C4-alkil, pentil, heksil, heptil ili oktil;
Halogen je npr. fluor, klor, brom, jod.
Izum se nadalje odnosi na one spojeve iz kojih se spojevi formule I mogu osloboditi (tzv. pred-lijekovi).
Prednosni pred-lijekovi su oni u kojima se oslobađanje odvija pod uvjetima kao što su oni koji vladaju u određenim dijelovima tijela, npr. u želucu, crijevima, krvotoku, jetri.
Izum se nadalje odnosi na upotrebu gore navedenih derivata karboksilnih kiselina za proizvodnju lijekova, naročito za proizvodnju inhibitora ETA i/ili ETB receptora.
Spojevi I i također intermedijati za njihovu proizvodnju, kao što je, na primjer, II, mogu imati jedan ili više asimetrično supstituiranih ugljikovih atoma. Takovi spojevi mogu postojati kao čisti enantiomeri ili čisti diastereomeri ili kao njihova smjesa. Pri upotrebi kao aktivne tvari, prednost se daje upotrebi enantiomerno čistog spoja.
Spojevi formule IIa, u kojoj A predstavlja C1-C4-alkil, azido, SR10 ili OR10 mogu se proizvesti kako je opisano u WO 96/11914, DE 19614533.3 ili DE 19726146.9.
[image]
Spojevi formule IIb, u kojoj A predstavlja SR10 ili OR10 mogu se dobiti u enantiomerno čistom obliku kiselo kataliziranom transeterifikacije, kako je opisano u DE 19636046.3.
Enantiomerno čisti spojevi formule II mogu se dobiti provedbom klasičnog rastavljanja s racemičnim ili diastereomernim spojevima formule II upotrebom prikladne enantiomerno čiste baze. Primjeri prikladnih baza te vrste jesu, na primjer, 4-klorfeniletilamin i baze spomenute u WO 96/11914.
Spojevi formule Ia prema izumu, u kojoj A predstavlja C1-C4-alkil, azido, SR10 ili OR10, a njihovi supstituenti imaju značenje dato za formulu I, mogu se proizvesti, na primjer, reakcijom derivata karboksilnih kiselina formule IIa, u kojoj supstituenti imaju navedena značenje, sa spojevima formule III.
[image]
R17 u formuli III je halogen ili R18 -SO2, gdje R18 može biti C1-C4-alkilf C1-C4-haloalkil ili fenil. Reakcija se odvija ponajprije u inertnom otapalu ili u sredstvu za razredivanje, uz dodatak prikladne baze, tj . baze koja deprotonira intermedijat IIa, pri temperaturi u području od sobne temperature do vrelišta otapala.
Spojevi tipa Ia u gdje R1 = COOH mogu se dobiti izravno na taj način ako se medusproizvod IIa, u kojem R1 predstavlja COOH, deprotonira upotrebom dva ekvivalenta odgovarajuće baze i reagira sa spojevima opće formule III. Ta se reakcija također odvija u inertnom otapalu i pri temperaturi u području od sobne temperature do vrelišta otapala.
Primjeri takovih otapala ili sredstava za razređivanje jesu alifatski, aliciklički i aromatski ugljikovodici, od kojih svaki može biti kloriran, kao, na primjer, heksan, cikloheksan, petrol eter, nafta, benzen, ksilen, metilen klorid, kloroform, tetraklorugljik, etil klorid i trikloretilen, eteri, kao diizopropil eter, dibutil eter, metil terc.butil eter, propilen oksid, dioksan i tetrahidrofuran, nitrili kao npr. acetonitril i propionitril, kiselinski amidi, kao npr. dimetilformamid, dimetilacetamid i N-metilpirolidon, sulfoksidi i sulfoni, kao, na primjer, dimetil sulfoksid i sulfolan.
Spojevi formule III su poznati ili se mogu proizvesti po opće poznatim metodama, kao na primjer:
H. Erlenmeyer, G. Bischoff, Helv. Chim. Acta, 29 (1946), 280-283, G. Kjellin, J. Sandstrom, Acta Scim. Scand., 23 (1969), 2879, E.R. Buchmann, A.O. Reims, H. Sargent, J. Org. Chem., 6 (1941), 764-766, F.C. James, H.D. Krebs, Aust. J. Chem., 35 (1982), 385-391, G.R. Humphrey, S.H.B. Wright, J. Heterocyclic Chem., 26 (1989), 23.
Kao baza može se upotrijebiti hidrid alkalijskog ili zemno alkalijskog metala, kao natrijev hidrid, kalijev hidrid ili kalcijev hidrid, karbonat kao karbonat alkalijskog metala, npr. natrijev ili kalijev karbonat, hidroksid alkalijskog ili zemno alkalijskog metala kao natrijev ili kalijev hidroksid, organometalni spoj kao butil-litij ili amid alkalijskog metala, kao litijev diizopropilamid ili litijev amid.
Spojevi fomrule IIb mogu reagirati slično metodama opisanim u DE 19726146.9, čime se dobiju spojevi Ib.
[image]
Spojevi formule I mogu se proizvesti također i tako da se pode od odgovarajućih karboksilnih kiselina, tj. spojeva formule I u kojoj R predstavlja COOH, i oni se najprije na uobičajen način prevedu u aktivirani oblik kao što je kiselinski halogenid, anhidrid ili imidazolid, a potonji zatim reagiraju s odgovarajućim hidroksilnim spojem HOR . Ta reakcija se može provesti u uobičajenim otapalima i često je potreban dodatak baze, pri čemu su prikladne one gore navedene. Obadva stupnja mogu se također pojednostavniti, na primjer, tako da se karboksilnu kiselinu pusti djelovati na hidroksilni spoj u prisutnosti sredstva za dehidrataciju, kao što je karbodiimid.
Osim toga, spojevi formule I mogu se također proizvesti i tako da se pode od soli odgovarajućih karboksilnih kiselina, tj. spojeva formule I u kojoj R1 predstavlja skupinu COOM, pri čemu M može biti kation alkalijskog metala ili ekvivalent kationa zemno alkalijskog metala. Te soli mogu reagirati s mnogim spojevima formule R-W, pri čemu W predstavlja uobičajenu nukleofilnu otpusnu skupinu, primjerice halogen, kao klor, brom, jod, ili nasupstituirani ili aril- ili alkilsulfonil supstituiran s halogenim, kao s klorom, bromom jodom, ili aril- ili alkilsulfonil koji nije supstituiran ili je supstituiran s halogenim, alkilom ili s haloalkilom, kao što je, na primjer, toluensulfonil i metilsulfonil ili s nekom drugom ekvivalentnom polaznom skupinom. Spojevi formule R-W s reaktivnim supstituentom W, su poznati ili se lako mogu dobiti na asnovi općeg stručnog znanja. Ta se reakcija može provesti u uobičajenim otapalima i odvija se prednosno uz dodatak baze, pri čemu su prikladne gore navedene.
U nekim slučajevima za pripravljanje spojeva I prema izumu moraju se primijeniti općenito poznati postupci sa zaštitnim skupinama. Ako, na primjer, R10 predstavlja 4-hidroksifenil, tada se hidroksilnu skupinu može najprije zaštititi kao benzilni eter, koji se zatim odcjepljuje u prikladnom stupnju reakcije.
Spojevi formule I u kojoj R1 predstavlja tetrazol mogu se proizvesti kako je opisano u WO 96/11914.
Što se tiče biološkog djelovanja, prednost se daje derivatima karboksilnih kiselina formule I kao čistim enantiomerima i čistim diastereomerima i kao njihovim smjesama, u kojima supstituenti imaju slijedeća značenja:
A je NR8R9, azido, OR10, SR10 ili C1-C4-alkil.
X je kisik, sumpor, CR11 ili NR11; pod uvjetom da ako X = CR11, tada Y = kisik ili sumpor ili NR14.
Y je kisik, sumpor, CR13 ili NR14; pod uvjetom da ako Y = kisik ili sumpor ili NR14, tada X = CR11.
R2 i R3 (koji mogu biti jednaki ili različiti) predstavljaju:
fenil ili naftil, koji može biti supstituiran s jednim ili više slijedećih radikala: halogen, nitro, cijano, hidroksil, merkapto, C1-C4-alkil, C1-C4-haloalkil, C1-C4-alkoksi, C1-C4-haloalkoksi, fenoksi, C1-C4-alkiltio, NH(C1-C4-alkil) ili N (C1-C4-alkil)2 ili fenil, koji može biti jednostruko do trostruko supstituiran s halogenim, cijano, C1-C4-alkilom, C1-C4-haloalkilom, C1-C4-alkoksi, C1-C4-haloalkoksi ili C1-C4-alkiltio; ili
fenil ili naftil, koji su međusobno povezani u orto položaju pomoću izravne veze, metilenske, etilenske ili etenilne skupine, kisikovog ili sumpornog atoma ili jedne SO2-, NH ili N-alkilne skupine;
C5-C6-cikloalkil, pri čemu tu radikali u svakom slučaju mogu biti jednostruko do trostruko supstituirani s halogenim, C1-C4-alkilom, C1-C4-alkoksi, C1-C4-alkiltio, C1-C4-haloalkoksi.
R4 i R11 (koji mogu biti jednaki ili različiti) predstavljaju:
C1-C4-alkil, pri čemu ti radikali mogu biti supstituirani s halogenim, hidroksilom;
vodik, halogen, C1-C4-alkoksi, C1-C4-haloalkoksi, C1-C4-alkiltio, hidroksil, NH2, NH (C1-C4-alkil) , N (C1-C4-alkil)2;
ili CR4 zajedno sa CR11 tvori petero- ili šesteročlani alkilenski prsten može biti jednostruko do trostruko supstituiran sa C1-C4-alkilom i u kojem u svakom slučaju jedna do tri metilenske skupine mogu biti nadomještene s kisikom ili sumporom.
R8 je vodik, C1-C4-alkil, C1-C4-alkilkarbonil, pri čemu ovi radikali u svakom slučaju mogu biti jednostruko do trostruko supstituirani s halogenim, hidroksilom, karboksilom, amino, C1-C4-alkoksi, C1-C4-alkiltio, C1-C4-haloalkoksi, C1-C4-alkoksikarbonilom, NH (C1-C4-alkilom), N (C1-C4-alkilom)2, C5-C6-cikloalkilom, fenilom, koji sa svoje strane može biti jednostruko do trostruko supstituiran s halogenim, C1-C4-alkilom, C1-C4-haloalkilom, C1-C4-alkoksi, C1-C4-haloalkoksi, C1-C4-alkiltio;
fenil, koji može biti jednostruko do trostruko supstituiran s halogenim, hidroksilom, C1-C4-alkilom, trifluormetilom, C1-C4-alkoksi, C1-C4-alkiltio, dioksometilenom ili dioksoetilenom;
C3-C6-cikloalkil, pri čemu ti radikali u svakom slučaju mogu biti jednostruko do trostruko supstituirani s halogenim, C1-C4-alkilom, C1-C4-alkoksi;
ili R8 zajedno s R9 tvori C4-C6-alkilenski lanac zatvoren u prsten, koji može biti jednostruko do trostruko supstituiran sa C1-C4-alkilom, C1-C4-haloalkilom, i u kojem alkilenska skupina može biti nadomještena s kisikom, kao -(CH2)4-, -(CH2)5-, -(CH2)6-, -(CH2)2-O-(CH2)2-,
R9 je vodik, C1-C4-alkil;
ili R9 je povezan s R8 u prsten, kako je navedeno za R8.
R10 je vodik, C1-C4-alkil, pri čemu ovi radikali u svakom slučaju mogu biti jednostruko do trostruko supstituirani s halogenim, hidroksilom, karboksilom, C1-C4-alkoksi, C1-C4-alkoksikarbonilom, karboksamidom, CONH (C1-C4-alkilom) , CON (C1-C4-alkilom)2, CONR15R16, NH (C1-C4-alkilom) , N (C1-C4-alkilom)2, C5-C6-cikloalkilom, fenilom, koji sa svoje strane može biti jednostruko do trostruko supstituiran s halogenim, hidroksilom, C1-C4-alkilom, C1-C4-alkilkarboksilom, trifluormetilom, C1-C4-alkoksi, NH(C1-C4-alkilom) , N (C1-C4-alkilom)2, fenilom ili C1-C4-alkiltio;
fenil koji može biti jednostruko do trostruko supstituiran s halogenim, hidroksilom, C1-C4-alkilom, C1-C4-haloalkilom, C1-C4-alkoksi, C1-C4-alkiltio, NH (C1-C4-alkilom) , N (C1-C4-alkilom)2, dioksometilenom ili diokso-etilenom;
C3-C8-cikloalkil, pri čemu ti radikali u svakom slučaju mogu biti jednostruko ili višestruko supstituirani s halogenim, C1-C4-alkilom, C1-C8-alkoksi.
R13 je vodik, halogen, C1-C4-alkil, trifluormetil.
R15 i R16 zajedno tvore C3-C7-alkilenski lanac zatvoren u prsten, na koji može biti fuzioniran fenilni prsten, kao što je 2,3-dihidroindol, indol, 1,3-dihidroizoindol, 1,2,3,4-tetrahidrokinolin, 1,2,3,4-tetrahidroizokinolin, pri čemu u svakom slučaju fenilni prsten može biti jednostruko do trostruko supstituiran s halogenim, C1-C4-alkilom, C1-C4-alkoksi, hidroksi;
R19 je metoksi ili etoksi, koji nosi jedan od slijedećih radikala: hidroksil, karboksil, C1-C4-alkoksi-karbonil, amino, NH (C1-C4-alkil) , N (C1-C4-alkil)2, karboksamid ili CON (C1-C4-alkil)2 .
Spojevi predloženog izuma nude novu terapeutsku mogućnost za liječenje hipertenzije, visokog plućnog tlaka, infarkta miokarda, angine pektoris, aritmija, akutnog/kroničnog otkazivanja bubrega, kronične srčane insuficijencije, renalne insuficijencije, cerebralnih vazospazmi, cerebralne ishemije, subarahnoidnih krvarenja, migrene, astme, ateroskleroze, endotoksičkog šoka, otkazivanja organa induciranih endotoksinom, intravaskularne koagulacije, restenoze nakon angioplastije i bypass operacija, benigne hiperplazije prostate, otkazivanja bubrega ili hipertenzije uzrokovane ishemijom i intoksikacijom, metastaziranja i rasta mezenhimalnih tumora kao što je rak prostate, otkazivanja bubrega induciranog kontratstnim sredstvom, pankreatitisa, gastrointestinalnih čireva.
Izum se nadalje odnosi na kombininacije endotelin receptor antagonista formule I i inhibitora sistema renin-angiotenzin. Inhibitori sistema renin-angiotenzin su inhibitori renina, angiotenzin II antagonisti i inhibitori enzima koji pretvara angiotenzin (ACE, e. angiotensine converting enzyme). Prednosne su kombinacije endotelin receptor antagonista formule I i ACE inhibitora.
Izum se nadalje odnosi na kombininacije endotelin receptor antagonista formule I i antagonista kalcija kao što je verapamil.
Izum se nadalje odnosi na kombininacije endotelin receptor antagonista formule I i beta-blokera.
Izum se nadalje odnosi na kombininacije endotelin receptor antagonista formule I i diuretika.
Izum se nadalje odnosi na kombininacije endotelin receptor antagonista formule I i tvari koje blokiraju djelovanje VEGF-a (vaskularni endotelijalni faktor rasta). Takove tvari jesu, na primjer, antitijela usmjerena protiv VEGF-a, ili specifični vezni proteini, ili alternativno tvari niske molekulske mase koje mogu specifično inhibirati oslobađanje VEGF-a ili vezanje receptora.
Gore spomenute kombinacije mogu se dati istovremeno ili odvojeno. To se može provesti na obadva načina, tj. u jednostrukoj farmaceutskoj formulaciji ili u odvojenim formulacijama. Način aplikacije također može biti različit, na primjer, endotelin receptor antagonisti mogu se dati oralno, a VEGF inhibitori parenteralno.
Ti kombinirani pripravci posebno su prikladni za liječenje i prevenciju hipertenzije i njenih posljedica, i također za liječenje srčane insufićijenkcije.
Dobar učinak spojeva može se pokazati pomoću slijedećih ispitivanja:
Proučavanje vezanja receptora
Za proučavanje vezanja koriste se klonirane CHO-stanice koje eksprimiraju ETA- ili ETB-receptor.
Priprava membrana
CHO-stanice, koje eksprimiraju ETA- ili ETB-receptor, rastu su DMEM NUT MIX F12-mediju (Gibco, br. 21331-020) s 10% fetalnog telećeg seruma (PAA Laboratories GmbH, Linz, br. A15-022), 1 mM glutamina (Gibco br. 25030-024), 100 U/ml penicilina i 100 µg/ml streptomicina (Gibco, Sigma br. P-0781) . Nakon 48 sati stanice se isperu s PBS-om i inkubiraju 5 minuta pri 37°C s PBS-om koji sadrži 0,05% tripsina. Nakon toga slijedi neutralizacija s medijem i stanice se skupe centrifugiranjem pri 300 x g.
Za pripravljanje membrana stanice se namjeste na koncentraciju od 108 stanica/ml pufera (50 ml tris HCl pufer, pH 7,4) i zatim se dezintegriraju ultrazvukom (Branson Sonifier 250, 40-70 sekundi/konstatno/učin 20).
Ispitivanja vezanja
Za ispitivanje vezanja ETA- i ETB-receptora membrane se suspendiraju u puferu za inkubaciju (50 mM tris HCl, pH 7,4 s 5 mM MnCl2, 40 mg/ml bacitracina i 0,2% BSA) u koncentraciji od 50 µg proteina po ispitnoj smjesi i inkubiraju se pri 25°C s 25 pM 125J-ET1 (ispitivanje ETA-receptora) ili 25 pM 125J-ET3 (ispitivanje ETB-receptora) u prisutnosti ili odsutnosti ispitne tvari. Nespecifično vezanje određuje se s 10-7 M ET1. Nakon 30 minuta razdvoje se slobodan i vezani radioligand filtriranjem kroz filtere od staklenih vlakana GF/B (Whatman, Engleska) na skupljaču stanica Skatron (Skatron, Lier, Norveška) i filteri se isperu s ledeno hladnim puferom tris HCl, pH 7,4 s 0,2% BSA. Radioaktivnost skupljena na filterima kvantitativno se utvrdi pomoću scintilacijskog brojača za tekućine Packard 2200 CA.
Ispitivanje ET-antagonista in vivo
Mužjaci SD štakora težine 250 - 300 g anestezirani su s amobarbitalom, priključeni na umjetno disanje, vagotomizirani i despinalizirani. Arteria carotis i vena jugularis bile su katetezirane.
U skupini kontrolnih životinja intravensko davanje 1 mg/kg ET1 dovelo je do jasnog porasta krvnog tlaka, koji se je održao tijekom relativno dugog vremena.
Pokusnim životinjama, 30 minuta prije davanja ET1, ubrizgani su ispitni spojevi i.v. (1 mg/kg). Za određivanje ET-antagonističkih svojstava porast krvnog tlaka pokusnih životinja bio je uspoređen s onim kod kontrolnih životinja.
p.o. - ispitivanje miješanih ETA- i ETB-antagonista:
Mužjaci normotenzivnih štakora (Sprague Dawley, Janvier) težine 250-350 g najprije su oralno primili ispitne tvari. 80 minuta kasnije životinje su anestezirane s uretanom, a arteria carotis (za mjerenje krvnog tlaka) kao i vena jugularis (aplikacija big endotelin/endotelin 1) su kateterizirane.
Nakon faze stabilizacije, intravenski je dat big endotelin (20 µg/kg, aplicirani volumen 0,5 ml/kg), ili ET1 (0,3 µg/kg, aplicirani volumen 0,5 ml/kg). Krvni tlak i srčana frekvencija registrirani su kontinuirano tijekom 30 minuta. Jasne i trajne promjene krvnog tlaka računate su kao površine ispod krivulje (AUC). Za određivanje antagonističkog djelovanja ispitnih tvari AUC životinja koje su primile ispitne tvari uspoređen je s AUC-om kontrolnih životinja.
Spojevi prema izumu mogu se davati na uobičajen način oralno ili parenteralno (subkutano, intravenski, intramuskuiarno, intraperitonealno). Aplikacije se također mogu izvršiti s parama ili sprejevima kroz nos-ždrijelo.
Doziranje ovisi o starosti, stanju i težini pacijenta, te o načinu aplikacije. U pravilu dnevna doza aktivnog spoja iznosi od približno 0,5 do 100 mg/kg tjelesne težine kod oralnog davanja i od približno 0,1 do 10 mg/kg tjelesne težine kod parenteralnog davanja.
Novi spojevi mogu se dati u uobičajenim krutim ili tekućim farmaceutskim oblicima, npr. kao tablete, s filmom prevučene tablete, kapsule, prašak, granule, prevučene tablete, čepići, otopine, masti, kreme ili sprejevi. Oni se proizvesti na uobičajen način. U tu svrhu aktivne tvari mogu se preraditi s uobičajenim farmaceuskim pomoćnim sredstvima kao što su veziva za tablete, punila, konzervansi, sredstva za rastvaranje tableta, sredstva za regulaciju tečenja, omekšivači, sredstva za kvašanje, disperzanti, emulgatori, otapala, sredstva za produženo oslobađanje aktivne tvari, antioksidanti i/ili potisni plinovi (usporedi H. Sucker et al.; Pharmazeutische Technologie, Thieme-Verlag, Stuttgart, 1991). Tako dobiveni aplikacijski oblici sadrže aktivnu tvar obično količinom od 0,1 do 90 mas. %.
Primjeri sinteze
Primjer 1
2-metilsulfonil-4,5-dimetiltiazol
2,7 g 2-metilmerkapto-4,5-dimetiltiazola stavi se najprije u metilen klorid pri temperaturi leda i doda se 5,9 g mCPBA. Smjesu se miješa 16 sati pri sobnoj temperaturi i zatim se ekstrahira jednom s otopinom natrijevog karbonata i s otopinom natrijevog tiosulfata. Organsku fazu se osuši preko magnezijevog sulfata, otapalo se izdestilira i izolira se 2,88 g ulja, koje se odmah dalje upotrebljava.
1H-NMR (200 MHz) : 3,25 ppm (3 H, s); 2,50 (3H, s); 2,40 (3H, s) .
ESI-MS: M+ - 191
Primjer 2
2-metilmerkapto-4,5-ciklopententiazol
10,4 g amonijevog ditiokarbamata stavi se najprije u etanol i doda se 7,5 g klorciklopentanona. Nakon 30 minuta reakcija je gotova i reakcijsku smjesu se prenese u vodu. Vodenu fazu se ponovno jako zaluži s otopinom natrijevog hidroksida, ekstrahira s metilen kloridom i zatim se namjesti na pH 2 s koncentriranom solnom kiselinom. Vodenu fazu se ekstrahira s etil acetatom, organsku fazu se osuši s magnezijevim sulfatom i otapalo se izdestilira. Ostatak se preuzme u toluen, doda se do vrhu punu žličicu p-toluensulfonske kiseline i otapalo se izdestilira pri 60°C. 7,9 g ulja otopi se u 75 ml vode i doda se 2,4 g NaOH i brzo, kap po kap, 5,7 ml dimetil sulfata. Nakon jednog sata reakcija je gotova i smjesu se prenese u vodu. Vodenu fazu se ekstrahira s eterom, organsku fazu se osuši s magnezijevimg sulfatom i otapalo se izdestilira. Ostatak se bez daljnjeg čišćenja koristi u slijedećoj reakciji.
Primjer 3
2-metilsulfonil-4,5-ciklopententiazol
1,9 g 2-metilmerkapto-4,5-ciklopententiazola stavi se najprije pri temperaturi leda u metilen klorid i doda se 7,3 g mCPBA. Smjesu se miješa 16 sati pri sobnoj temperaturi i zatim se ekstrahira jednom s 1N otopinom natrijevog karbonata i s otopinom natrijevog tiosulfata. Organsku fazu se osuši preko magnezijevog sulfata, otapalo se izdestilira i izolira se 2,25 g ulja, koje se odmah dalje upotrebljava.
1H-NMR (200 MHz) : 3,26 ppm (3 H, s); 3,05 (2H, dd) ; 2,95 (2H, dd)/ 2,55 (2H, dddd).
ESI-MS: M+ = 203
Primjer 4
2-metilsulfonil-4,5-dimetiloksazol
3 g 2-metilsulfonil-4,5-dimetiloksazola otopi se u 100 ml metilen klorida i pri temperaturi leda i doda se 13 g mCPBA. Smjesu se miješa tri sata i zatim doda otopinu natrijevog tiosulfata. Neutralizira s natrijevim hidrogenkarbonatom i proizvod se ekstrahira s metilen kloridom. Nakon sušenja preko magnezijevog sulfata, otapalo se izdestilira i izolira se 2 g sirovog proizvoda, koji se odmah može dalje upotrijebiti.
1H-NMR (200 MHz): 3,30 ppm (3 H, s); 2,35 (3H, s); 2,15 (3H, s) .
ESI-MS: M+ = 175
Primjer 5
(S)-2-(4,5-dimetiltiazol-2-iloksi)-3-metoksi-3,3-difenil-propinska kiselina (I-1)
320 mg 55%-tnog NaH doda se najprije k mješavini od 1 g S-2-hidroksi-3-metsoki-3,3-difenilpropionske kiseline u 20 ml THF/20 ml DMF-a i smjesu se miješa 15 minuta. K tome se doda se 700 mg 2-metilsulfonil-4,5-dimetiloksazola i to se miješa 16 sati pri sobnoj temepraturi. Smjesu se zatim obradi s vodom, zakiseli s limunskom kiselinom i proizvod se esktrahira s eterom. Nakon sušenja preko magnezijevog sulfata i destilacije otapala, proizvod se očisti kromatografijom i kristalizira iz eter/n-heksana. Izolirano je 522 mg kristala.
1H-NMR (200 MHz): 7,35-7,20 ppm (10H, m); 6,25 (1H,s); 3,30 (3 H, s); 2,25 (3H, s); 2,20 (3H, s).
ESI-MS: M+ = 383
Primjer 6
2-(4,5-ciklopentenotiazol-2-iloksi)-3-(2-(3, 4-dimetoksifenil)-etoksi-3,3-difenilpropinska kiselina (I-17)
1H-NMR (200 MHz): 7,30-7,20 ppm (10H, m); 6,80-6,60 (3H, m); 6,25 (1H, s); 3,85 (3 H, s); 3,80 (3H, s); 3,70-3,40 (2H, m), 2,9-2,6 (4H, m); 2.30-2,25 (2H, m).
ESI-MS: M+ = 545
2-(4,5-dimetiltiazol-2-iloksi)-3-(2-(3,4-dimetoksifenil)-etoksi-3,3-difenilpropinska kiselina (I-15)
1H-NMR (200 MHz): 7,30-7,20 ppm (10H, m); 6,80-6,60 (3H, m); 6,00 (1H, s); 3,85 (3 H, s); 3,80 (3H, s); 3,70-3,40 (2H, m); 2,80 (2H, tr); 2,10 (3H, s); 1,90 (3H, s).
ESI-MS: M+ = 517
(S)-2-(benzotiazol-2-iloksi)-3-metoksi-3,3-difenilpropinska kiselina (I-6)
1H-NMR (200 MHz): 7,70-7,50 ppm (2H, m); 7,35-7,20 (12H, m); 6,50 (1H, s); 3,30 (3H, s).
ESI-MS: M+ - 40
(S)-2-(4,5~ciklopentenotiazol-2-iloksi)-3-metoksi-3,3-difenilpropinska kiselina (I-5)
1H-NMR (200 MHz) : 7,50-7,20 ppm (10H, m); 6,40 (1H, s); 3,30 (3 H, s); 2,80-2,60 (4H, m); 2,30 (2H, m).
ESI-MS: M+ - 395
(S)-2-(4,5-dimetiltiazol-2-iloksi)-3-metoksi-3,3-difenil-propinska kiselina (I-4)
1H-NMR (200 MHz): 7,50-7,20 ppm (10H, m); 6,10 (1H, s); 3,25 (3H, s); 2,1 (3H, s); 1,90 (3H, m).
ESI-MS: M+ = 367
2-(4,5-dimetiltiazol-2-iloksi)-3-(2-(3,4-dimetoksifenil)-etoksi-3,3-difenilpropinska kiselina (I-13)
1H-NMR (200 MHz): 7,30-7,20 ppm (10H, m); 6,70-6,50 (3H, m); 6,20 (1H, s); 3,90 (3 H, s); 3,85 (3H, s); 3,70-3,40 (2H, m); 2,80 (2H, tr); 2,20 (3H, s); 1,15 (3H, s).
ESI-MS: M+ = 533.
Na isti način ili kako je opisano u općem dijelu mogu se proizvesti spojevi navedeni u tablici 1.
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
Primjer 7
U skladu s gore opisanim ispitivanjem vezanja, podaci o vezanju receptora izmjereni su za dolje navedene spojeve.
Rezultati su prikazani u slijedećoj tablici 2.
Tablica 2
Podaci za vezanje receptora (Ki-vrijednosti)
[image]
Claims (9)
1. Derivat heterociklički supstituirane α-hidroksi-karboksilne kiseline formule I
[image]
naznačen time, da
R1 predstavlja tetrazolil ili skupinu
[image]
u kojoj
R ima slijedeća značenja:
a) radikal OR5 gdje R5 predstavlja
vodik, kation alkalijskog metala, kation zemno alkalijskog metala ili fiziološki podnošljiv organski amonijev ion;
C3-C8-cikloalkil, C1-C8-alkil, CH2-fenil, C3-C8-alkenil, C3-C8-alkinil, u svakom slučaju nesupstituiran ili supstituiran;
b) peteročlani heteroaromatski sistem povezan preko dušikovog atoma;
c) skupina
[image]
u kojoj k može imati vrijednost 0, 1 i 2, p može biti 1, 2, 3 i 4 i R6 je
C1-C4-alkil, C3-C8-cikloalkil, C3-C8-alkenil, C3-C8-alkinil ili nesupstituiran ili supstituiran fenil;
d) radikal formule
[image]
u kojoj R7 je
C1-C4-alkil, C3-C8-alkenil, C3-C8-alkinil, C3-C8-ciklo-alkil, pri čemu ti radikali mogu nositi C1-C4-alkoksi, C1-C4-alkiltio i/ili fenilni radikal;
C1-C4-haloalkil ili fenil, koji je nesupstituiran ili supstituiran;
A je NR8R9, azido, OR10, SR10 ili C1-C4-alkil,
X je kisik, sumpor, CR11 ili NR12; pod uvjetom da ako X = CR11, tada Y = kisik ili sumpor ili NR14;
Y je kisik, sumpor, CR13 ili NR14; pod uvjetom da ako Y - kisik ili sumpor ili NR14, tada X = CR11;
R2 i R3 (koji mogu biti jednaki ili različiti) predstavljaju:
fenil ili naftil, koji je nesupstituiran ili supstituiran; ili
fenil ili naftil, koji su međusobno povezani u orto položajima preko izravne veze, metilenske, etilenske ili etenilne skupine, kisikovog ili sumpornog atoma ili jedne SO2-, NH ili N(C1-C4-alkilne) skupine;
C5-C6-cikloalkil, koji je nesupstituiran ili supstituiran;
R4 i R11 (koji mogu biti jednaki ili različiti) predstavljaju:
vodik, halogen, C1-C4-alkoksi, C1-C4-haloalkoksi, C3-C6-alkeniloksi, C3-C6-alkiniloksi, C1-C4-alkiltio, C1-C4-alkilkarbonil, C1-C4-alkoksikarbonil, hidroksil, NH2, NH(C1-C4-alkil) , N (C1-C4-alkil)2
C1-C4-alkil, C2-C4-alkenil, C2-C4-alkinil, pri čemu ovi radikali mogu biti nesupstituirani ili supstituirani;
ili CR4 zajedno sa CR11 tvori petero- ili šesteročlani alkilenski ili alkenilenski prsten, može biti nesupstituiran ili supstituiran, i u kojem u svakom slučaju jedna ili više metilenskih skupina može biti nadomješteno s kisikom, sumporom, -NH ili NH(C1-C4-alkilom);
R8 je vodik, C1-C8-alkil, C3-C8-alkenil ili C3-C8-alkinil, C1-C5-alkilkarbonil, pri čemu ovi radikali u mogu biti nesupstituirani ili supstituirani;
fenil ili naftil; koji je nesupstituiran ili supstituiran;
nesupstituirani ili supstituirani C3-C8-cikloalkil;
ili R9 zajedno s R8 tvori C3-C7-alkilenski lanac, koji može biti nesupstituiran ili supstituiran, koji je zatvoren u prsten i u kojem jedna alkilenska skupina može biti nadomještena s kisikom ili sumporom;
R9 je vodik, C1-C4-alkil;
ili R9 je povezan s R8 u prsten, kako je navedeno kod R8;
R10 je vodik, C1-C8-alkil, C3-C8-alkenil ili C3-C8-alkinil, pri čemu ovi radikali u svakom slučaju mogu biti nesupstituirani ili supstituirani; fenil ili naftil, koji je nesupstituiran ili supstituiran;
nesupstituirani ili supstituirani C3-C8-cikloalkil;
R12 je vodik, C1-C4-alkil;
ili NR12 zajedno sa CR4 tvori petero- ili šesteročlani alkilenski ili alkenilenski prsten koji može biti jednostruko do trostruko supstituiran sa C1-C4-alkilom, i u kojem u svakom slučaju jedna ili više metilenskih skupina kiselina može biti nadomješteno s kisikom ili sumporom;
R12 je vodik, C1-C4-alkil;
R13 je vodik, halogen, C1-C4-alkil, C2-C4-alkenil, C2-C4-alkinil, pri čemu ti radikali mogu biti nesupstituirani ili supstituirani;
R14 je vodik, C1-C4-alkil;
i njihove fiziološki podnošljive soli, i mogući enantiomerno čisti i diastereoizomerno čisti oblici.
2. Upotreba heterociklički supstituiranih derivata α-hidroksi-karboksilnih kiselina I prema zahtjevu 1, naznačena time, da se oni koriste za liječenje bolesti.
3. Upotreba spojeva I prema zahtjevu 2, naznačena time, da se oni koriste kao endotelin receptor antagonisti.
4. Upotreba derivata heterociklički supstituiranih α-hidroksi-karboksilnih kiselina I prema zahtjevu 1, naznačena time, da se oni koriste za proizvodnju lijekova ili za liječenje bolesti kod kojih se pojavljuje povišena azina endotelina.
5. Upotreba derivata heterociklički supstituiranih α-hidroksi-karboksilnih kiselina I prema zahtjevu 1, naznačena time, da se oni koriste za proizvodnju lijekova za liječenje bolesti u kojima endotelin doprinosi uzroku i/ili progresiji bolesti.
6. Upotreba derivata heterociklički supstituiranih α-hidroksi-karboksilnih kiselina I prema zahtjevu 1, naznačena time, da se oni koriste za liječenje kronične srčane insuficijencije, restenoze, visokog krvnog tlaka, visokog plućnog tlaka, akutnog/kroničnog otkazivanja bubrega, cerebralne ishemije, benigne hiperplazije prostate i raka prostate.
7. Kombinacija derivata heterociklički supstituiranih α-hidroksi-karboksilnih kiselina I prema zahtjevu 1, naznačena time, da sadrži jedan ili više aktivnih spojeva odabranih između inhibitora sistema renin-angiotenzina kao što su inhibitori renina, angiotenzin II antagonisti, inhibitora enzima koji pretvara angiotenzin (ACE), miješanih inhibitora ACE/neutralne endopeptidaze (NEP), β-blokera, diuretika, antagonista kalcija i tvari koje blokiraju VEGF.
8. Farmaceutski pripravak za oralnu i parenteralnu upotrebu, naznačen time, da u pojedinačnoj dozi, osim uobičajenih pomoćnih tvari za lijekove, sadrži najmanje jedan derivat karboksilne kiseline I prema zahtjevu 1.
9. Strukturni fragment formule
[image]
naznačen time, da radikali R1, R2, R3, R4, X i Y imaju značenja navedena u zahtjevu 1, kao strukturni fragment u endotelin receptor antagonistu.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19750529A DE19750529A1 (de) | 1997-11-14 | 1997-11-14 | Neue heterocyclisch substituierte alpha-Hydroxycarbonsäurederivate, ihre Herstellung und Verwendung als Endothelinrezeptorantagonisten |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP980591A2 true HRP980591A2 (en) | 1999-08-31 |
Family
ID=7848772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR19750529.5A HRP980591A2 (en) | 1997-11-14 | 1998-11-13 | Novel heterocyclically substituted alpha-hydroxycarboxylic acid derivatives, their preparation and use as endothelin receptor antagonists |
Country Status (23)
Country | Link |
---|---|
US (1) | US6358983B1 (hr) |
EP (1) | EP1037883A1 (hr) |
JP (1) | JP2001523671A (hr) |
KR (1) | KR20010032083A (hr) |
CN (1) | CN1278805A (hr) |
AR (1) | AR017581A1 (hr) |
AU (1) | AU752165B2 (hr) |
BG (1) | BG104400A (hr) |
BR (1) | BR9814157A (hr) |
CA (1) | CA2308746A1 (hr) |
CO (1) | CO4990973A1 (hr) |
DE (1) | DE19750529A1 (hr) |
HR (1) | HRP980591A2 (hr) |
HU (1) | HUP0004341A3 (hr) |
ID (1) | ID24819A (hr) |
IL (1) | IL135461A0 (hr) |
NO (1) | NO20002154L (hr) |
NZ (1) | NZ504289A (hr) |
PL (1) | PL340756A1 (hr) |
SK (1) | SK4932000A3 (hr) |
TR (1) | TR200001365T2 (hr) |
WO (1) | WO1999025701A1 (hr) |
ZA (1) | ZA9810425B (hr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1750862T3 (pl) * | 2004-06-04 | 2011-06-30 | Teva Pharma | Kompozycja farmaceutyczna zawierająca irbesartan |
MY146830A (en) * | 2005-02-11 | 2012-09-28 | Novartis Ag | Combination of organic compounds |
US7790770B2 (en) * | 2005-11-23 | 2010-09-07 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
-
1997
- 1997-11-14 DE DE19750529A patent/DE19750529A1/de not_active Withdrawn
-
1998
- 1998-11-04 BR BR9814157-0A patent/BR9814157A/pt not_active IP Right Cessation
- 1998-11-04 SK SK493-2000A patent/SK4932000A3/sk unknown
- 1998-11-04 HU HU0004341A patent/HUP0004341A3/hu unknown
- 1998-11-04 ID IDW20000882A patent/ID24819A/id unknown
- 1998-11-04 WO PCT/EP1998/007026 patent/WO1999025701A1/de not_active Application Discontinuation
- 1998-11-04 IL IL13546198A patent/IL135461A0/xx unknown
- 1998-11-04 PL PL98340756A patent/PL340756A1/xx not_active Application Discontinuation
- 1998-11-04 AU AU14878/99A patent/AU752165B2/en not_active Ceased
- 1998-11-04 NZ NZ504289A patent/NZ504289A/en unknown
- 1998-11-04 CA CA002308746A patent/CA2308746A1/en not_active Abandoned
- 1998-11-04 JP JP2000521084A patent/JP2001523671A/ja active Pending
- 1998-11-04 KR KR1020007005207A patent/KR20010032083A/ko not_active Application Discontinuation
- 1998-11-04 CN CN98811085A patent/CN1278805A/zh active Pending
- 1998-11-04 EP EP98958900A patent/EP1037883A1/de not_active Withdrawn
- 1998-11-04 TR TR2000/01365T patent/TR200001365T2/xx unknown
- 1998-11-04 US US09/530,382 patent/US6358983B1/en not_active Expired - Fee Related
- 1998-11-09 AR ARP980105651A patent/AR017581A1/es not_active Application Discontinuation
- 1998-11-13 HR HR19750529.5A patent/HRP980591A2/hr not_active Application Discontinuation
- 1998-11-13 ZA ZA9810425A patent/ZA9810425B/xx unknown
- 1998-11-13 CO CO98067231A patent/CO4990973A1/es unknown
-
2000
- 2000-04-27 NO NO20002154A patent/NO20002154L/no not_active Application Discontinuation
- 2000-05-04 BG BG104400A patent/BG104400A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
BG104400A (en) | 2001-01-31 |
WO1999025701A1 (de) | 1999-05-27 |
JP2001523671A (ja) | 2001-11-27 |
AR017581A1 (es) | 2001-09-12 |
HUP0004341A3 (en) | 2001-12-28 |
SK4932000A3 (en) | 2001-02-12 |
NZ504289A (en) | 2002-03-01 |
CA2308746A1 (en) | 1999-05-27 |
AU752165B2 (en) | 2002-09-05 |
AU1487899A (en) | 1999-06-07 |
NO20002154L (no) | 2000-05-12 |
KR20010032083A (ko) | 2001-04-16 |
TR200001365T2 (tr) | 2000-09-21 |
BR9814157A (pt) | 2000-10-03 |
IL135461A0 (en) | 2001-05-20 |
EP1037883A1 (de) | 2000-09-27 |
US6358983B1 (en) | 2002-03-19 |
PL340756A1 (en) | 2001-02-26 |
ID24819A (id) | 2000-08-24 |
HUP0004341A1 (hu) | 2001-10-28 |
NO20002154D0 (no) | 2000-04-27 |
CN1278805A (zh) | 2001-01-03 |
CO4990973A1 (es) | 2000-12-26 |
ZA9810425B (en) | 2000-05-15 |
DE19750529A1 (de) | 1999-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP980560A2 (en) | New carboxylic acid derivatives, carrying amido side-chains, their production and use as endothelin receptor antagonists | |
HRP970686A2 (en) | Heterocyclic carboxylic acid derivatives, their preparation and use as endothelin receptor antagonists | |
HRP980331A2 (en) | New beta-amino and beta-azido carboxylic acid derivatives, the production and the use thereof as endothelin receptor antagonists | |
HRP980591A2 (en) | Novel heterocyclically substituted alpha-hydroxycarboxylic acid derivatives, their preparation and use as endothelin receptor antagonists | |
HRP980484A2 (en) | Novel carboxylic acid derivatives, their production and their their use as mixed eta/etb receptor antagonists | |
HRP20000602A2 (en) | 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists | |
HRP20000650A2 (en) | Novel unsymmetrically substituted carboxylic acid derivatives, method for producing them, and their use as mixed et<->a<p>/et<->b<p> receptor antafonists | |
HRP20010164A2 (en) | New carboxylic acid derivatives carrying keto side-chains, their production and their use as endothelin-receptor antagonists | |
KR20010101279A (ko) | 신규 β-아미드 및 β-설폰아미드 카르복실산 유도체,그의 제조 방법 및 엔도텔린 수용체 길항제로서의 그의 용도 | |
MXPA02000616A (es) | Derivados de acidos carboxilicos, novedosos, con anillo pirimidina sustituido en las posiciones 5, 6, su preparacion y uso como antagonistas de los receptores para endotelina. | |
CA2375666A1 (en) | Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists | |
MXPA00004506A (en) | NOVEL HETEROCYCLICALLY SUBSTITUTED&agr;-HYDROXYCARBOXLIC ACID DERIVATIVES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | |
MXPA01001246A (en) | New carboxylic acid derivatives carrying keto side-chains, their production and their use as endothelin-receptor antagonists | |
HRP970503A2 (en) | Novel carboxylic acid derivatives, their production and their use as mixed eta/etb receptor antagonists | |
MXPA00006463A (en) | 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists | |
MXPA00001479A (en) | Novel carboxylic acid derivatives, their production and their use as mixed eta | |
CZ20002963A3 (cs) | Nové deriváty karboxylové kyseliny, obsahující 5- substituovaný pyrimidinový kruh, jejich příprava a použiti |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
OBST | Application withdrawn |